Seroatlas · Human Serome Atlas

TRAF7

E3 ubiquitin-protein ligase TRAF7

Also known as: DKFZp586I021, MGC7807, RFWD1, RNF119, TRAF7_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q6Q0C0
Gene
TRAF7
Ensembl
ENSG00000131653
Chromosome
16
Canonical length
670 aa
Protein class
Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
Subcellular location
Vesicles
Quaternary structure
Homodimer

OverviewNCBI Gene

Tumor necrosis factor (TNF; see MIM 191160) receptor-associated factors, such as TRAF7, are signal transducers for members of the TNF receptor superfamily (see MIM 191190). TRAFs are composed of an N-terminal cysteine/histidine-rich region containing zinc RING and/or zinc finger motifs; a coiled-coil (leucine zipper) motif; and a homologous region that defines the TRAF family, the TRAF domain, which is involved in self-association and receptor binding.[supplied by OMIM, Apr 2004]

Canonical amino-acid sequenceUniProt

670 residues, UniProt reviewed canonical sequence.

>Q6Q0C0|TRAF7
     1  MSSGKSARYN RFSGGPSNLP TPDVTTGTRM ETTFGPAFSA VTTITKADGT STYKQHCRTP
    61  SSSSTLAYSP RDEEDSMPPI STPRRSDSAI SVRSLHSESS MSLRSTFSLP EEEEEPEPLV
   121  FAEQPSVKLC CQLCCSVFKD PVITTCGHTF CRRCALKSEK CPVDNVKLTV VVNNIAVAEQ
   181  IGELFIHCRH GCRVAGSGKP PIFEVDPRGC PFTIKLSARK DHEGSCDYRP VRCPNNPSCP
   241  PLLRMNLEAH LKECEHIKCP HSKYGCTFIG NQDTYETHLE TCRFEGLKEF LQQTDDRFHE
   301  MHVALAQKDQ EIAFLRSMLG KLSEKIDQLE KSLELKFDVL DENQSKLSED LMEFRRDASM
   361  LNDELSHINA RLNMGILGSY DPQQIFKCKG TFVGHQGPVW CLCVYSMGDL LFSGSSDKTI
   421  KVWDTCTTYK CQKTLEGHDG IVLALCIQGC KLYSGSADCT IIVWDIQNLQ KVNTIRAHDN
   481  PVCTLVSSHN VLFSGSLKAI KVWDIVGTEL KLKKELTGLN HWVRALVAAQ SYLYSGSYQT
   541  IKIWDIRTLD CIHVLQTSGG SVYSIAVTNH HIVCGTYENL IHVWDIESKE QVRTLTGHVG
   601  TVYALAVIST PDQTKVFSAS YDRSLRVWSM DNMICTQTLL RHQGSVTALA VSRGRLFSGA
   661  VDSTVKVWTC

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRAF7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.37
Highest tissue expression
53 nTPM

Expression across tissuesHPA

Tissue

  • esophagus: 53 nTPM
  • liver: 49 nTPM
  • skin: 46 nTPM
  • cerebellum: 43 nTPM
  • colon: 37 nTPM
  • pancreas: 36 nTPM

Single-cell type

  • esophageal apical cells: 105 nCPM
  • esophageal suprabasal cells: 89 nCPM
  • esophageal basal cells: 82 nCPM
  • enterocytes: 74 nCPM
  • decidual stromal cells: 73 nCPM
  • tuft cells: 58 nCPM

Immune cell

  • intermediate monocyte: 5 nTPM
  • non-classical monocyte: 4.3 nTPM
  • myeloid DC: 4.1 nTPM
  • classical monocyte: 3.2 nTPM
  • T-reg: 3.2 nTPM
  • eosinophil: 3.1 nTPM

Brain region

  • medulla oblongata: 32 nTPM
  • cerebral cortex: 32 nTPM
  • thalamus: 31 nTPM
  • cerebellum: 31 nTPM
  • hippocampal formation: 30 nTPM
  • choroid plexus: 29 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TRAF7.

Disease | AllUniProt

Conditions TRAF7 is implicated in, by any mechanism.

  • Cardiac, facial, and digital anomalies with developmental delay (CAFDADD) MIM:618164

Disease | GeneticClinVar

21 pathogenic / likely-pathogenic of 256 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Cardiac, facial, and digital anomalies with developmental delay
  • TRAF7-related disorder
  • Inborn genetic diseases
  • TRAF7-related syndrome
  • TRAF7-associated heart defect-digital anomalies-facial dysmorphism-motor and speech delay syndrome

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.46
gnomAD pLI
0.02
gnomAD missense Z
3.26
DepMap mean gene effect
-0.18
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TRAF7 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRAF7 as an antibody target. Whether an autoantibody or antibody against TRAF7 could matter depends on whether native TRAF7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRAF7 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TRAF7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/TRAF7. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...